Taccone FS, Van den Abeele AM, Bulpa P, Misset B, Meersseman W, Cardoso T, et al. Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes. Crit Care. 2015;19:7. https://doi.org/10.1186/s13054-014-0722-7.

Article  PubMed  PubMed Central  Google Scholar 

Matthews H, Rohde H, Wichmann D, Kluge S. Invasive pulmonary aspergillosis. Dtsch Med Wochenschr. 2019;144:1218–22. https://doi.org/10.1055/a-0817-7432.

Article  PubMed  Google Scholar 

Salazar F, Bignell E, Brown GD, Cook PC, Warris A. Pathogenesis of respiratory viral and fungal coinfections. Clin Microbiol Rev. 2022;35: e0009421. https://doi.org/10.1128/CMR.00094-21.

Article  PubMed  Google Scholar 

Prattes J, Koehler P, Hoenigl M, Group E-CS. COVID-19 associated pulmonary aspergillosis: regional variation in incidence and diagnostic challenges. Intensive Care Med. 2021;47:1339–40. https://doi.org/10.1007/s00134-021-06510-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koehler P, Bassetti M, Chakrabarti A, Chen SCA, Colombo AL, Hoenigl M, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2021;21:e149–62. https://doi.org/10.1016/S1473-3099(20)30847-1.

Article  CAS  PubMed  Google Scholar 

Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63:e1–60. https://doi.org/10.1093/cid/ciw326.

Article  PubMed  PubMed Central  Google Scholar 

Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24:e1–38. https://doi.org/10.1016/j.cmi.2018.01.002.

Article  PubMed  Google Scholar 

Maertens JA, Rahav G, Lee DG, Ponce-de-Leon A, Ramirez Sanchez IC, Klimko N, et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet. 2021;397:499–509. https://doi.org/10.1016/S0140-6736(21)00219-1.

Article  CAS  PubMed  Google Scholar 

Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol. 2004;57:218–22. https://doi.org/10.1046/j.1365-2125.2003.01977.x.

Article  PubMed  PubMed Central  Google Scholar 

Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53:958–66. https://doi.org/10.1128/aac.01034-08.

Article  CAS  PubMed  Google Scholar 

Koeck JA, Hilgarth H, von Ameln-Mayerhofer A, Meyn D, Warlich R, Münstedt A, et al. Clinically relevant interactions with anti-infectives on intensive care units—a Multicenter Delphi Study. Antibiotics (Basel). 2021. https://doi.org/10.3390/antibiotics10111330.

Article  PubMed  PubMed Central  Google Scholar 

Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, Courtney R. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother. 2004;48:3543–51. https://doi.org/10.1128/aac.48.9.3543-3551.2004.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sime FB, Stuart J, Butler J, Starr T, Wallis SC, Pandey S, et al. A pharmacokinetic case study of intravenous posaconazole in a critically ill patient with hypoalbuminaemia receiving continuous venovenous haemodiafiltration. Int J Antimicrob Agents. 2018;52:506–9. https://doi.org/10.1016/j.ijantimicag.2018.07.008.

Article  CAS  PubMed  Google Scholar 

Maruo Y, Iwai M, Mori A, Sato H, Takeuchi Y. Polymorphism of UDP-glucuronosyltransferase and drug metabolism. Curr Drug Metab. 2005;6:91–9. https://doi.org/10.2174/1389200053586064.

Article  CAS  PubMed  Google Scholar 

Li Y, Theuretzbacher U, Clancy CJ, Nguyen MH, Derendorf H. Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet. 2010;49:379–96. https://doi.org/10.2165/11319340-000000000-00000.

Article  CAS  PubMed  Google Scholar 

Ueda K, Nannya Y, Kumano K, Hangaishi A, Takahashi T, Imai Y, et al. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol. 2009;89:592–9. https://doi.org/10.1007/s12185-009-0296-3.

Article  CAS  PubMed  Google Scholar 

Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother. 2011;55:4782–8. https://doi.org/10.1128/aac.01083-10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gubbins PO, Krishna G, Sansone-Parsons A, Penzak SR, Dong L, Martinho M, et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother. 2006;50:1993–9. https://doi.org/10.1128/AAC.00157-06.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krishna G, Ma L, Martinho M, O’Mara E. Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. Antimicrob Agents Chemother. 2012;56:4196–201. https://doi.org/10.1128/AAC.00222-12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jansen AME, Muilwijk EW, van der Velden W, Maertens JA, Aerts R, Colbers A, et al. Posaconazole bioavailability of the solid oral tablet is reduced during severe intestinal mucositis. Clin Microbiol Infect. 2022;28:1003–9. https://doi.org/10.1016/j.cmi.2022.01.029.

Article  CAS  PubMed  Google Scholar 

Mian P, Trof RJ, Beishuizen A, Masselink JB, Cornet AD, Sportel ET. Suboptimal plasma concentrations with posaconazole suspension as prophylaxis in critically ill COVID-19 patients at risk of Covid-associated pulmonary aspergillosis. J Clin Pharm Ther. 2022;47:383–5. https://doi.org/10.1111/jcpt.13518.

Article  CAS  PubMed  Google Scholar 

Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801–10. https://doi.org/10.1001/jama.2016.0287.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270:2957–63. https://doi.org/10.1001/jama.270.24.2957.

Article  PubMed  Google Scholar 

Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71:1367–76. https://doi.org/10.1093/cid/ciz1008.

Article  PubMed  Google Scholar 

Chen L, Wang Y, Zhang T, Li Y, Meng T, Liu L, et al. Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis. BMC Infect Dis. 2018;18:155. https://doi.org/10.1186/s12879-018-3055-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Van Daele R, Brüggemann RJ, Dreesen E, Depuydt P, Rijnders B, Cotton F, et al. Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation. J Antimicrob Chemother. 2021;76:1234–41. https://doi.org/10.1093/jac/dkab012.

Article  CAS  PubMed  Google Scholar 

Cornely OA, Duarte RF, Haider S, Chandrasekar P, Helfgott D, Jiménez JL, et al. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. J Antimicrob Chemother. 2015;71:718–26. https://doi.org/10.1093/jac/dkv380.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sime FB, Stuart J, Butler J, Starr T, Wallis SC, Pandey S, et al. Pharmacokinetics of intravenous posaconazole in critically ill patients. Antimicrob Agents Chemother. 2018. https://doi.org/10.1128/aac.00242-18.

Article  PubMed  PubMed Central  Google Scholar 

Van Daele R, Wauters J, Dreesen E, Boelens J, Nulens E, Lormans P, et al. Exposure to intravenous posaconazole in critically ill patients with influenza: a pharmacokinetic analysis of the POSA-FLU study. Mycoses. 2022;65:656–60. https://doi.org/10.1111/myc.13446.

Article  CAS  PubMed  Google Scholar 

Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102:433–44. https://doi.org/10.3324/haematol.2016.152900.

Article  PubMed  PubMed Central  Google Scholar 

Seyedmousavi S, Mouton JW, Verweij PE, Brüggemann RJM. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. Expert Rev Anti Infect Ther. 2013;11:931–41. https://doi.org/10.1586/14787210.2013.826989.

Article  CAS  PubMed